Duodenal Crohn’s disease successfully treated with adalimumab

Upper gastrointestinal involvement in Crohn’s disease is considered to be relatively infrequent (0.4 – 3%) [1], and treatment mainly relies on the use of high doses of proton pump inhibitors, mesalazine (mesalamine), and steroids [2]. A 37-year-old woman was admitted for observation in November 2009 because of diarrhea, epigastric pain, iron-deficiency anemia, and weight loss (6 kg in 2 months). Gastroscopy found large ulcers in the second portion of the duodenum, with reduction of duodenal folds (Fig. 1). The result of histological examination of the specimens was compatible with active Crohn’s disease (Fig. 2), and computed tomography excluded any other gastrointestinal localization. The patient started treatment with azathioprine 2.5 mg/kg per day, pantoprazole 80 mg/day, and adalimumab (160 mg at week 0 and 80 mg at week 2 to induce remission, followed by maintenance treatment with 40 mg every 2 weeks). She responded immediately to the therapy, with immediate epigastric pain relief. Her weight recovered within 4 months, and all laboratory tests became normal within 3 months. At the first endoscopic follow-up (February 2010) we noted complete healing of the large ulcers and restoration of histology, which persisted until the last follow-up (August 2010) (Fig. 3). At the present date the patient is still taking pantoprazole 40 mg/day and adalimumab 40 mg every 2 weeks (azathioprine was discontinued after 6 months), and is in complete remission. Anti-TNFα therapy has hitherto been regarded only as an alternative therapy for severe or refractory disease [2 – 4]. This is the first case report describing successful treatment of adult primary duodenal Crohn’s disease with adalimumab. The case is also interesting because we used adalimumab as the first therapeutic strategy on appearance of the disease. This “top-down” approach resulted in more rapid remission than the conventional “step-up” treatment, with a faster reduction in clinical symptoms, rapid decline in laboratory inflammatory markers, and rapid endoscopic mucosal healing without the use of steroids [5].

References

Corresponding author
A. Tursi, MD
Servizio di Gastroenterologia Territoriale
DSS No. 4, ASL BAT
Via Torino, 49
70031 Andria (BA)
Italy
Fax: +39-0883-1978210
antotursi@tiscali.it

Tursi A. Duodenal Crohn’s disease successfully treated with adalimumab... Endoscopy 2011; 43: E22